SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Nelson Mandela Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientNelson Mandela
Date of birth1918-07-18
IdentifiersMRN HR-ML021-SYN-TD; SSN (made up) 000-21-6718
Document date2026-11-01
AuthorThandiwe Mokoena, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

First visit after a biopsy diagnosis of localized prostate cancer: risk group, staging, baseline before treatment, and radiation oncology referral. Concerns: Wants to understand a new diagnosis of prostate cancer after a rising PSA, and what treatment would mean at his age and with his commitments; Wants to keep his travel and public work going during treatment. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolideOne tablet once daily for four weeksOral route2001-04-14 to 2001-05-12completedS
Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapyOne injection every twelve weeks, two dosesIntramuscular route2001-04-21 to 2001-10-06completedS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2001-04-14activeS
Tamsulosin 0.4 mg oral capsule, one capsule by mouth once daily after the evening meal, for urinary frequency during radiotherapyOne capsule once daily in the eveningOral route2001-08-18activeS

Procedures

ProcedureDatesStatusEvidence
Multiparametric MRI of the prostate: gland volume 28 mL with a resection defect from the earlier operation; 9 mm PI-RADS 4 lesion in the left peripheral zone at the mid-gland; no extraprostatic extension, seminal vesicle invasion, or enlarged pelvic nodes2001-01-20 to 2001-01-20completedS
MRI-ultrasound fusion transperineal biopsy of the prostate, at the urology practice: adenocarcinoma, Gleason 4+3 (Grade Group 3) in 1 of 2 targeted cores (30 percent of the core) and in 2 of 12 systematic cores (Gleason 3+4, 10 and 15 percent); 3 of 14 cores in all; no perineural invasion2001-02-10 to 2001-02-10completedS
Gallium-68 PSMA PET/CT for staging: uptake only in the left peripheral zone of the prostate; no nodal, bone, or visceral disease (N0 M0)2001-03-31 to 2001-03-31completedS
Transperineal insertion of three gold fiducial markers into the prostate for image guidance, with planning CT and MRI2001-07-07 to 2001-07-07completedS
Image-guided intensity-modulated radiotherapy to the prostate and proximal seminal vesicles, 74 Gy in 37 daily fractions over about seven and a half weeks, with curative intent; no pelvic nodal radiation2001-07-24 to 2001-09-14completedS
Advance care planning conversation, about 20 minutes2001-06-09 to 2001-06-09completedS

Immunizations

DateVaccineStatusEvidence
2000-10-21High-dose influenza vaccine, last seasoncompletedS
1994-05-14Tdap vaccinecompletedS
2001-10-27High-dose influenza vaccine, this seasoncompletedS
2001-06-09Pneumococcal conjugate vaccine PCV20completedS
2001-06-09Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1985Operation on the prostate for an enlarged gland causing urinary blockage, with part of the gland removed (type of operation not recorded in the cited sources)D (CLM-0003)
12 August 1988Tuberculosis, diagnosed after admission to hospital and treatedD (CLM-0004)
November 2000Raised PSA found on routine monitoring, followed by a prostate biopsyD (CLM-0005)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Wants to understand a new diagnosis of prostate cancer after a rising PSA, and what treatment would mean at his age and with his commitmentsactiveS
Wants to keep his travel and public work going during treatmentcurrentS

Assessment

Most recent measures: Prostate specific Ag [Mass/volume] in Serum or Plasma 0.4 on 2001-10-27; Testosterone [Mass/volume] in Serum or Plasma 38 on 2001-10-27; Hemoglobin [Mass/volume] in Blood 14.1 on 2001-03-10; Leukocytes [#/volume] in Blood by Automated count 5.8 on 2001-03-10; Platelets [#/volume] in Blood by Automated count 226 on 2001-03-10; Sodium [Moles/volume] in Serum or Plasma 140 on 2001-03-10; Potassium [Moles/volume] in Serum or Plasma 4.4 on 2001-03-10; Glucose [Mass/volume] in Serum or Plasma 94 on 2001-03-10; Creatinine [Mass/volume] in Serum or Plasma 1.08 on 2001-03-10; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1996)/1.73 sq M 69 on 2001-03-10; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2001-03-10; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 on 2001-03-10; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 74 on 2001-03-10; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2001-03-10; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2001-03-10; Cholesterol [Mass/volume] in Serum or Plasma 184 on 2001-03-10; Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 on 2001-03-10; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 112 on 2001-03-10; Triglyceride [Mass/volume] in Serum or Plasma 98 on 2001-03-10; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2001-07-14; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2001-03-10; International Prostate Symptom Score [IPSS] 12 on 2001-10-27; DXA Femur [T-score] Bone density -1.4 on 2001-04-14; DXA Lumbar spine [T-score] Bone density -0.6 on 2001-04-14; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2001-06-09; Total score [Mini-Cog] 5 on 2001-06-09; Total score [AUDIT-C] 0 on 2001-06-09 [S]

Strengths and supports: Supports: family, close friends, and a personal assistant who manages his schedule [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate canceractiveconfirmed C61S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D).
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognitionactiveconfirmed Z79.899S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
History of pulmonary tuberculosis, treated, with no symptoms sinceresolvedconfirmed Z86.11S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic.
Personal history of external beam radiotherapy to the prostateactiveconfirmed Z92.3S — Synthetic: recorded after the course of radiotherapy finished.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2001-03-10Prostate specific Ag [Mass/volume] in Serum or Plasma6.4ng/mL<=4 ng/mLHighS
2001-03-10Testosterone [Mass/volume] in Serum or Plasma412ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationNormalS
2001-03-10Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-16.6 g/dLNormalS
2001-03-10Leukocytes [#/volume] in Blood by Automated count5.810*3/uL4-11 10*3/uLNormalS
2001-03-10Platelets [#/volume] in Blood by Automated count22610*3/uL150-400 10*3/uLNormalS
2001-03-10Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2001-03-10Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2001-03-10Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2001-03-10Creatinine [Mass/volume] in Serum or Plasma1.08mg/dL0.74-1.35 mg/dLNormalS
2001-03-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1996)/1.73 sq M69mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2001-03-10Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
2001-03-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-55 U/LNormalS
2001-03-10Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma74U/L40-129 U/LNormalS
2001-03-10Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2001-03-10Hemoglobin A1c/Hemoglobin.total in Blood5.5%<=5.6%NormalS
2001-03-10Cholesterol [Mass/volume] in Serum or Plasma184mg/dL<=200 mg/dLNormalS
2001-03-10Cholesterol in HDL [Mass/volume] in Serum or Plasma52mg/dL>=40 mg/dLNormalS
2001-03-10Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation112mg/dL<=129 mg/dLNormalS
2001-03-10Triglyceride [Mass/volume] in Serum or Plasma98mg/dL<=149 mg/dLNormalS
2001-03-1025-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma26ng/mL30-100 ng/mLLowS
2001-03-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2001-03-10International Prostate Symptom Score [IPSS]7{score}S
2001-04-14DXA Femur [T-score] Bone density-1.4{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisLowS
2001-04-14DXA Lumbar spine [T-score] Bone density-0.6{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisNormalS
2001-04-14Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2001-07-14Prostate specific Ag [Mass/volume] in Serum or Plasma0.9ng/mL<=4 ng/mLNormalS
2001-07-14Testosterone [Mass/volume] in Serum or Plasma18ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationLowS
2001-07-1425-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
2001-07-14Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2001-10-27Prostate specific Ag [Mass/volume] in Serum or Plasma0.4ng/mL<=4 ng/mLNormalS
2001-10-27Testosterone [Mass/volume] in Serum or Plasma38ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationLowS
2001-10-27International Prostate Symptom Score [IPSS]12{score}S
2001-10-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2001-06-09Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2001-06-09Total score [Mini-Cog]5{score}S
2001-06-09Total score [AUDIT-C]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2001-03-10Body height183cmS
2001-03-10Body weight80.2kgS
2001-03-10Body mass index (BMI) [Ratio]23.9kg/m2S
2001-03-10Systolic blood pressure132mm[Hg]S
2001-03-10Diastolic blood pressure78mm[Hg]S
2001-03-10Heart rate68/minS
2001-03-10Respiratory rate14/minS
2001-03-10Body temperature36.6CelS
2001-03-10Oxygen saturation in Arterial blood by Pulse oximetry97%S
2001-04-14Body height183cmS
2001-04-14Body weight80.4kgS
2001-04-14Body mass index (BMI) [Ratio]24kg/m2S
2001-04-14Systolic blood pressure130mm[Hg]S
2001-04-14Diastolic blood pressure76mm[Hg]S
2001-04-14Heart rate66/minS
2001-04-14Respiratory rate14/minS
2001-04-14Body temperature36.7CelS
2001-04-14Oxygen saturation in Arterial blood by Pulse oximetry97%S
2001-07-14Body height183cmS
2001-07-14Body weight81.6kgS
2001-07-14Body mass index (BMI) [Ratio]24.4kg/m2S
2001-07-14Systolic blood pressure134mm[Hg]S
2001-07-14Diastolic blood pressure78mm[Hg]S
2001-07-14Heart rate70/minS
2001-07-14Respiratory rate14/minS
2001-07-14Body temperature36.6CelS
2001-07-14Oxygen saturation in Arterial blood by Pulse oximetry97%S
2001-10-27Body height183cmS
2001-10-27Body weight81.4kgS
2001-10-27Body mass index (BMI) [Ratio]24.3kg/m2S
2001-10-27Systolic blood pressure128mm[Hg]S
2001-10-27Diastolic blood pressure74mm[Hg]S
2001-10-27Heart rate68/minS
2001-10-27Respiratory rate14/minS
2001-10-27Body temperature36.7CelS
2001-10-27Oxygen saturation in Arterial blood by Pulse oximetry98%S
2001-06-09Body height183cmS
2001-06-09Body weight81kgS
2001-06-09Body mass index (BMI) [Ratio]24.2kg/m2S
2001-06-09Systolic blood pressure132mm[Hg]S
2001-06-09Diastolic blood pressure76mm[Hg]S
2001-06-09Heart rate68/minS
2001-06-09Respiratory rate14/minS
2001-06-09Body temperature36.6CelS
2001-06-09Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
2001-03-10First visit after a biopsy diagnosis of localized prostate cancer: risk group, staging, baseline before treatment, and radiation oncology referralfinishedS
2001-04-14Five-week follow-up with radiation oncology consultation: staging result, shared decision on treatment, start of androgen deprivation, and bone densityfinishedS
2001-07-14Three-month follow-up on androgen deprivation before radiotherapy: PSA, testosterone, vitamin D, and side effectsfinishedS
2001-10-27Follow-up six weeks after radiotherapy: PSA, urinary and bowel effects, end of androgen deprivation, and the surveillance planfinishedS
2001-06-09Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Radiation oncology consultation to review staging and discuss curative treatment options and short-term androgen deprivationcompletedGL-AUA-ASTRO-PCA-2022-I, GL-NCCN-PROSTATE-2026S
Staging for unfavorable intermediate-risk disease with PSMA PET/CTcompletedGL-NCCN-PROSTATE-2026, GL-CMID-2026S
Treatment chosen through shared decision-making: image-guided external beam radiotherapy to the prostate with six months of androgen deprivation (leuprolide, with bicalutamide for the first four weeks)completedGL-AUA-ASTRO-PCA-2022-I, GL-AUA-ASTRO-PCA-2022-III, GL-NCCN-PROSTATE-2026S
Androgen deprivation monitoring: testosterone, PSA, blood pressure, glucose and lipids, DXA at baseline and every one to two years, vitamin D and calcium, hot flashes, mood, and cognitioncompletedGL-CMID-2026, GL-ACS-PCA-SURV-2014S
After radiotherapy: PSA every six months for five years, then yearly, with recurrence defined as a rise of 2 ng/mL above the nadir (Phoenix); urinary and bowel symptoms at every visitcompletedGL-CMID-2026, GL-NCCN-PROSTATE-2026, GL-ACS-PCA-SURV-2014S
Distress screening at each visit, physical activity, and a written survivorship care plancompletedGL-ACS-PCA-SURV-2014, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Reach an informed, shared decision on treatment after hearing every reasonable option, including observation2001-04-14completedRadiotherapy with six months of androgen deprivation chosen at the radiation oncology consultationS
Complete six months of androgen deprivation and the course of radiotherapy with side effects managed2001-10-27completedTwo leuprolide depots and 37 fractions completed; testosterone castrate on treatment; mild hot flashes and urinary frequency, managedS
Protect bone health on androgen deprivation: baseline DXA, vitamin D of 30 ng/mL or more, dietary calcium, and weight-bearing exercise2001-07-14completedFemoral neck T-score -1.4; vitamin D 34 ng/mL on supplementation; walking dailyS
PSA falling after radiotherapy, with a written surveillance plan2001-10-27completedPSA 0.4 ng/mL six weeks after radiotherapy; PSA every six months plannedS

Functional Status

Mental Status